These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12823628)

  • 41. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
    Tan GS; McKenna PM; Koser ML; McLinden R; Kim JH; McGettigan JP; Schnell MJ
    Virology; 2005 Jan; 331(1):82-93. PubMed ID: 15582655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and fowlpox virus boost HIV type 1 vaccine regimens in macaques.
    Pamungkas J; De Rose R; Iskandriati D; Noviana R; Paramastri Y; Dale CJ; Shoobridge M; Medveczky CJ; Ramshaw IA; Thomson S; Kent SJ
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):292-300. PubMed ID: 15943571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.
    Liang F; Lindgren G; Sandgren KJ; Thompson EA; Francica JR; Seubert A; De Gregorio E; Barnett S; O'Hagan DT; Sullivan NJ; Koup RA; Seder RA; Loré K
    Sci Transl Med; 2017 Jun; 9(393):. PubMed ID: 28592561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sustained peptide-specific gamma interferon T-cell response in rhesus macaques immunized with human immunodeficiency virus gag DNA vaccines.
    Caulfield MJ; Wang S; Smith JG; Tobery TW; Liu X; Davies ME; Casimiro DR; Fu TM; Simon A; Evans RK; Emini EA; Shiver J
    J Virol; 2002 Oct; 76(19):10038-43. PubMed ID: 12208982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dendritic cells as a conduit to improve HIV vaccines.
    Pope M
    Curr Mol Med; 2003 May; 3(3):229-42. PubMed ID: 12699360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
    Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
    J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies.
    Chege GK; Burgers WA; Müller TL; Gray CM; Shephard EG; Barnett SW; Ferrari G; Montefiori D; Williamson C; Williamson AL
    Vaccine; 2017 Feb; 35(6):929-937. PubMed ID: 28069361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques.
    Abimiku AG; Franchini G; Tartaglia J; Aldrich K; Myagkikh M; Markham PD; Chong P; Klein M; Kieny MP; Paoletti E
    Nat Med; 1995 Apr; 1(4):321-9. PubMed ID: 7585061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-HIV env immunities elicited by nucleic acid vaccines.
    Shiver JW; Davies ME; Yasutomi Y; Perry HC; Freed DC; Letvin NL; Liu MA
    Vaccine; 1997 Jun; 15(8):884-7. PubMed ID: 9234539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
    Marovich MA; Mascola JR; Eller MA; Louder MK; Caudrelier PA; El-Habib R; Ratto-Kim S; Cox JH; Currier JR; Levine BL; June CH; Bernstein WB; Robb ML; Schuler-Thurner B; Steinman RM; Birx DL; Schlesinger-Frankel S
    J Infect Dis; 2002 Nov; 186(9):1242-52. PubMed ID: 12402193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients.
    Kundu SK; Engleman E; Benike C; Shapero MH; Dupuis M; van Schooten WC; Eibl M; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):551-60. PubMed ID: 9591709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
    Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
    J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding and exploiting dendritic cells in human immunodeficiency virus infection using the nonhuman primate model.
    Barratt-Boyes SM; Brown KN; Melhem N; Soloff AC; Gleason SM
    Immunol Res; 2006; 36(1-3):265-74. PubMed ID: 17337787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.